Authorized purpose: Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.
Clinical role
Multimodality image viewing, perfusion analysis, reporting, and acute-stroke workflow support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain, cerebral vasculature, and perfusion regions
Key limitation
Keep in mind: The FDA labeling limits use to adults and supported imaging criteria. Inadequate bolus, motion, hemorrhage, and other exclusions require professional assessment; C-arm CT perfusion is qualitative and is not for thrombectomy selection.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain, cerebral vasculature, and perfusion regions Input: DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data including diffusion-weighted and dynamic studies.
Who uses it?Intended users: Trained professionals, including physicians and medical technicians.
What does the software produce?Output: Images, perfusion maps, tissue-flow and blood-volume values, mismatch and volumetric analyses, reports, and C-arm perfusion qualitative results.
What is its most important limitation?Key limitation: The FDA labeling limits use to adults and supported imaging criteria. Inadequate bolus, motion, hemorrhage, and other exclusions require professional assessment; C-arm CT perfusion is qualitative and is not for thrombectomy selection.
Clinical takeaway. Clinical role: Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports phantom validation testing characterizing perfusion imaging performance on conventional CT and C-arm CT scanners, stating accurate representation of key processing parameters under clinically relevant parameters and perturbations, and comparable conventional CT and C-arm CT results with small biases in MTT and Tmax expected from temporal resolution differences; it also reports software verification and validation meeting all design requirements and specifications, and validation through phantoms and case data. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.
The FDA labeling limits use to adults and supported imaging criteria. Inadequate bolus, motion, hemorrhage, and other exclusions require professional assessment; C-arm CT perfusion is qualitative and is not for thrombectomy selection.
The exact FDA document reports phantom validation testing characterizing perfusion imaging performance on conventional CT and C-arm CT scanners, stating accurate representation of key processing parameters under clinically relevant parameters and perturbations, and comparable conventional CT and C-arm CT results with small biases in MTT and Tmax expected from temporal resolution differences; it also reports software verification and validation meeting all design requirements and specifications, and validation through phantoms and case data. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "iSchemaView conducted extensive phantom validation testing of the Rapid System for characterizing the perfusion imaging performance of conventional CT and C-arm CT scanners." … "The performance validation testing demonstrated that the Rapid system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports phantom validation testing characterizing perfusion imaging performance on conventional CT and C-arm CT scanners, stating accurate representation of key processing parameters under clinically relevant parameters and perturbations, and comparable conventional CT and C-arm CT results with small biases in MTT and Tmax expected from temporal resolution differences; it also reports software verification and validation meeting all design requirements and specifications, and validation through phantoms and case data. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "iSchemaView conducted extensive phantom validation testing of the Rapid System for characterizing the perfusion imaging performance of conventional CT and C-arm CT scanners." … "The performance validation testing demonstrated that the Rapid system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software.". Read from the exact FDA decision document on 2026-11-14.
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K233582 FDA evidence package for Rapid
DesignFDA 510(k) decision evidence and product verification for the exact submission.
PopulationBrain, cerebral vasculature, and perfusion regions
Scopeexact submission
Tested versionRapid
IndependenceSponsor or vendor study
K233582
FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
No record matched K233582 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data including diffusion-weighted and dynamic studies.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes DICOM data received from files, media, or network sources and processed by a Rapid Server connected to the hospital LAN or firewall.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA package describes a dedicated or virtual Rapid Server on a standard computer or VMware virtual platform; current hosting, security, availability, and local routing remain unknown.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Images, perfusion maps, tissue-flow and blood-volume values, mismatch and volumetric analyses, reports, and C-arm perfusion qualitative results.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes a dedicated or virtual Rapid Server on a standard computer or VMware virtual platform; current hosting, security, availability, and local routing remain unknown.
The FDA package describes DICOM data received from files, media, or network sources and processed by a Rapid Server connected to the hospital LAN or firewall.
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
Vendor-wide
Checked 2026-10-25
This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.
Use by trained professionals, including physicians and medical technicians. Follow the exact labeling, local training, supervision, and escalation requirements.
The FDA package describes a dedicated or virtual Rapid Server on a standard computer or VMware virtual platform; current hosting, security, availability, and local routing remain unknown.
The FDA package describes DICOM data received from files, media, or network sources and processed by a Rapid Server connected to the hospital LAN or firewall.
Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads
No evidence was promoted. All records use rapid as a generic word or concern unrelated diseases, methods, or interventions; none identifies the Rapid imaging product, tested version, or K233582. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price or commercial contract for the exact submission and version was identified.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product payer coverage or reimbursement determination was identified in reviewed public material.
Authorized purpose: Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: Rapid Platform v6.0 is image-processing software for trained professionals that views, processes, and analyzes DICOM images from CT and MRI. It supports functional and dynamic datasets including CT perfusion, CT angiography, diffusion-weighted MRI, and dynamic contrast-enhanced CT or MRI, with maps and measurements for tissue perfusion, diffusion, and blood volume. Rapid CT-Perfusion and Rapid MR-Perfusion may aid physicians in selecting acute stroke patients with known occlusion of the intracranial internal carotid artery or proximal middle cerebral artery for endovascular thrombectomy, subject to the labeled imaging criteria, clinical requirements, and exclusions.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain and intracranial vessels represented in CT perfusion, CTA, and MRI; tissue perfusion, diffusion, and contrast dynamics
Authorized purpose: Rapid processes CT, CTP, CTA, diffusion MRI, and dynamic-contrast MRI for stroke viewing, perfusion, volumetry, mismatch, and large-vessel-density support for trained professionals.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: Neuro.Al Algorithm processes static, functional, dynamic, and derived CT or MR images to support brain perfusion analysis, tissue blood-volume and parametric-map review, ventricular visualization, and DICOM return to clinical viewers for trained professional interpretation.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.